September 2, 2015 Evidentiary Considerations for Integration of Biomarkers in Drug Development Symposium Evidentiary Considerations for Integration of Biomarkers in Drug Development Symposium On August 21st, the University of Maryland&
August 30, 2015 Critical Path Institute’s Polycystic Kidney Disease Outcomes Consortium Secures FDA Qualification for Enrichment Biomarker in Autosomal Dominant Polycystic Kidney Disease (ADPKD) August 31, 2015 Critical Path Institute’s Polycystic Kidney Disease Outcomes Consortium Secures FDA Qualification for Enrich
July 14, 2015 The Predictive Safety Testing Consortium: Safety Biomarkers, Collaboration, and Qualification
January 6, 2015 Critical Path Institute Secures Regulatory Support For Autosomal Dominant Polycystic Kidney Disease (ADPKD) Biomarker June 1, 2015 Critical Path Institute Secures Regulatory Support For Autosomal Dominant Polycystic Kidney Disease (ADPKD) Biomarke
April 27, 2015 Critical Path Institute Secures Regulatory Support For Parkinson’s And Alzheimer’s Disease Biomarkers April 27, 2015 Critical Path Institute Secures Regulatory Support For Parkinson’s And Alzheimer’s Disease Biomarkers F
April 13, 2015 Critical Path Institute Secures Regulatory Support For Skeletal Muscle Safety Biomarkers April 13, 2015 Critical Path Institute Secures Regulatory Support For Skeletal Muscle Safety Biomarkers FDA and EMA Letters of Sup
January 12, 2015 Critical Path Institute Secures Additional Regulatory Support For Kidney Safety Biomarkers January 12, 2015 Critical Path Institute Secures Additional Regulatory Support For Kidney Safety Biomarkers EMA Letter of Support
April 28, 2014 Nonclinical Safety Biomarkers of Drug-induced Vascular Injury: Current Status and Blueprint for the Future
